Join our daily newsletter At The Bell to receive exclusive market insights
- Biopharmaceutical company Bionomics (BNO) has initiated trials to test a new tablet form of its post-traumatic stress disorder treatment (PTSD), BNC210
- The trial will test the drug’s new solid dose formula after its initial liquid formulation failed to meet efficacy standards in phase two trials
- Findings will then be used to determine the dosing regimen of BNC210 for a second phase two clinical trial, expected later this year
- A statement from BNO indicates the study site has been prepared and volunteer screenings have commenced
- Results from the study are expected in the first quarter of 2021
- BNO shares are up a healthy 3.45 per cent on the market
Biopharmaceutical company Bionomics (BNO) has initiated trials to test a new tablet formula of its post-traumatic stress disorder (PTSD) treatment, BNC210.
The trial will test the drug’s new solid dose formula after its initial liquid formulation failed to meet efficacy standards in phase two trials.
Findings will then be used to determine the dosing regimen of BNC210 to be given to PTSD patients in a second phase two clinical.
Previous pharmacokinetic data, which measures how a drug is absorbed when administered, found the tablet does not have to be taken with food and can still reach blood levels required to achieve exposures to give significant results in PTSD patients.
A statement from BNO indicates the study site has been prepared and screenings for healthy volunteers have commenced.
Bionomics Executive director Dr Errol De Souza said he is pleased with the progress made in overcoming limitations from the previous formula.
“We continue on our previously communicated timelines to confirm the
pharmacokinetic profile of the optimized BNC210 tablet to demonstrate that blood exposures predicted from the pharmacometric modelling are not only achieved but are maintained for a period of at least seven days,” he explained.
Results from the study are expected early this year, with a phase two PTSD study with the new tablet formulation projected for mid-2021.
BNO shares are up a healthy 3.45 per cent on the market, trading at 15 cents each at 3:02 pm AEDT.
